Clopidogrel: A New Antiplatelet Drug

Heart Disease

Volumn 2, Issue 2, 2000, Pages 168-173

  Lerner, Robert G ^a   Frishman, William H ^a   Mohan, K T ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ST BARNABAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

CHEMISTRY; CLINICAL TRIAL; DRUG INTERACTION; HUMAN; REVIEW;

CLINICAL TRIALS; DRUG INTERACTIONS; HUMAN; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 0034157715     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308: 81-106.
2. Thebault JJ, Baltrix CE, Blanchard JF, Panak EA. Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther 1975;18:485-490.
3. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet dependent disease states. Drug 1987;34:222-262.
4. McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet dependent disorders. Drugs 1990;40: 238-259.
5. Defreyn G, Bernat A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine; a review. Sem Thromb Hemost 1989;15:159-166.
6. Thebault JJ, Kiefefr G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 1999;25(suppl 2):3-8.
7. Thebault JJ, Kieffer G, Lowe GDO, Nimmo WS, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 1999;25(suppl 2):9-14.
8. Schror K. Antiplatelet drugs: a comparative review. Drugs 1995;50:7-28.
9. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-318.
10. Thornton MA, Gruentzig AR, Hollman J, King SB III, Douglas JS. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 1984;69:721-27.
11. Frishman WH, Chu R, Landzberg BR, Weiss M. Medical therapies for the prevention of restenosis following percutaneous coronary interventions. Curr Probl Cardiol 1998;23:533-640.
12. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100: 1667-1672.
13. Gaarder A, Jonsen J, Laaland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961;192:531-532.
14. Born GVR, Adenosine diphosphate is a mediator of platelet aggregation in vivo: an editorial view. Circulation 1985;72:741-746.
15. Reimers HJ. Adenine nucleotides in blood platelets. In, Longneck GL (ed): The Platelets: Physiology and Pharmacology. Orlando: Academic Press Inc., 1985;85-112.
16. Moritz MW, Reimers RC, Baker RK, Sutera SP, Joist JH. Role of cytoplasmic and releasable ADP in platelet aggregation induced by laminar shear stress. J Lab Clin Med 1983;101:537-544.
17. Rajagopalan S, McIntire LV, Hall ER, Wu KK. The stimulation of arachidonic acid metabolism in human platelets by hydrodynamic stress. Biochim Biophys Acta 1988;958:108-115.
18. Escolar G, Bastida K, Castillo R, Ordinas A. Ticlopidine inhibits platelet throm bus formation studied in a flowing system. Thromb Res 1987;45:.561-571.
19. Vindlacheruvu RR, Rink TJ Sage SO. Lack of evidence for lipoxygenase path way increases in cytosolic calcium evoked by ADP and arachidonic acid in human platelets. FEBS Lett 1991;292:196-200.
20. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear induced platelet aggregation can be mediated by VWF released From platelets, as well as by exogenous large or unusually large VWF multimers, requires adenosine-diphosphate, and is resistant to aspirin. Blood 1988;71:1366-1374.
21. Ratnatunga CP, Edmondson SF, Rees GM, Kovacs IB. High dose aspirin inhibits shear induced platelet reaction involving thrombin generation, Circulation 1992;85:1077-1082.
22. Yao S-K, Ober JC, McNatt J, et al. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992;70:39-48.
23. Cahill M, Mistry R, Barnett DB. The human platelet fibrinogen receptor clinical and therapeutic significance. Br J Clin Pharmacol 1992;33:2-9.
24. McFarlane DF, Srivastava PC, Mills CD. I-methyl thio adenosine diphosphate an agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest 1983;71:420-428.
25. Cooper DMF, Rodbell M. ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature 1979;282:517-518.
26. Soslau G, Parker I. Modulation of platelet Function by extracellular adenosinetriphosphate. Blood 1989;74:984-993.
27. Savi P, Heilmann E, Nurden P. Clopidogrel: an antithrombotic drug acting on the ADP dependent activation pathway of human platelets. Clin Appl Thromb Hemost 1996;2:35-42.
28. Plavix (Clopidogrel bisulphate) package insert. New York: Sanofi Pharmaceuticals Inc., 1998.
29. Coukell AJ, Markham A. Clopidogrel. Drugs 1997;54:745-750.
30. Mills DCB, Puri R, Hu GJ, Minniti G, Grana G, Fredeman MD, Colman RF, Colman RW. Clopidogrel inhibits binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb Vasc Biol 1992;68:430-436.
31. Humbert M, Nurden P, Bihour G, et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 1996;16:1532-1543.
32. Gacher C, Cattaneo M, Ohlmann P, et al. Purinoreceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haemotol 1995;91:434-444.
33. Hourani SM, Hall DA. Receptors for ADP on human blood platelets. Trends Pharmacol Sci 1994;15:103-108.
34. Savi P, Beauverger P, Labourer C, et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998;422:291-295.
35. 3-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991; 65:186-190.
36. 1. Biochem Pharmacol 1990;40:2683-2687.
37. Sharis PJ, Cannon GP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129:394-405.
38. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995;49:856-884.
39. Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993;4:252-261.
40. Feuerstein G, Nichols AJ, Ruffolo RR Jr. Clopidogrel: a novel antiplatelet drug tfor prevention and treatment of thrombotic disorders. Exp Opin Invest Drugs 1995;4:425-430.
41. Herbert J-M. Clopidogrel and antiplatelet therapy. Exp Opin Invest Drugs 1994;3:449-455.
42. Savi P, Bernat A, Dumas A, Ait-Chek L, Herbert JM. Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells. Thromb Res 1994;73:117-124.
43. Savi P, Pereillo JM, Andrieu A, Fedeli O, Reversat JL, Maftouh M, et al. Structure and activity of the active metabolite of clopidogtel. Thromb Haemost 1999;(suppl ):230.
44. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, Herbert JM. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-317.
45. Pederson AK, Fitzgerald GA. Dose-related kinetics of aspirin. Presystemic acctylation of platelet cyclooxygenase. N Engl J Med 1984;311:1206-1211.
46. Gambino MC, Passaghe S, Chen ZM, Bucchi F, Gori G, Latini R, de-Gaetano G, Cerletti C. Selectivity of oral aspirin as an inhibitor platelet vs vascular cyclooxygenase activity is reduced by portocaval shunt in rats. J Pharmacol Exp Ther 1988;245:287-290.
47. McEwen J, Strauch G, Perles P, Pritchard G, Moreland TE, Necciari J, Dickinson JP. Clopidogrel bioavailability: absence of influence of food or antacids. Semin Thromb Hemost 1999;25(suppl 2):47-50.
48. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999;25(suppl 2):25-28.
49. 14C-labeled clopidogrel. Semin Thromb Hemostat 1999;25(suppl 2):29-33.
50. Derat G, Brouard R, Bagnis C, et al. Safety and activity of clopidogrel, an antiplatelet agent, in chronic renal failure patients (abstract). J Am Soc Nephrol 1995;6(suppl 1):384.
51. Easton JD. Clinical aspects of the use of clopidogrel, a new antiplatelet agent. Semin Thromb Hemost 1999;25(suppl 2):77-82.
52. Gullin M-C, Bonnet G, Sissman J, et al. Pharmacodynamics and pharmacokinetics of the novel antiplatelet agent, clopidogrel, in the young and elderly with and without symptomatic atherosclerosis (abstract), Eur Heart J 1996;17:161.
53. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel vs aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339.
54. Leimbach ME, Peyrou V, Marzec UM, Chronos NAF, King III SB, Marker LA. Single-dose elopidogrel inhibition of platelet adenosine receptor function in patients with atherosclerotic coronary artery disease. Circulation 1999;100(supp I):681.
55. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatefet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
56. Harker LA, Marzec UM, Kelly AB, Chronos NR, Sundell IB, Hanson SR, Herbert JM. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998;98:2461-2469.
57. Makkar RR, Eigler NL, Kaul S, Frimerman A, Nakamura M, Shall PK, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stem thrombosis. Eur Heart J 1998;19:1538-1546.
58. Jauhar R, Bergman G, Savino S, Deutsch E, Shaknovich A, Parikh M, Sanborn TA. Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting. Am J Cardiol 1999;84:726-728.
59. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99:2364-2366.
60. Mishkel GJ, Aguirre FV, Ligon RW, Rocha-Singh KJ, Lucore CL, for Prairie Cardiovascular Consultants I.td.. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999;34:1884-1890.
61. Berger TE, Bell MR, Ribal CS, Ting H, Bareness G, Garratt K, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999; 34:1891-1894.
62. Klein LW, Calvin JE. Use of clopidogrel in coronary stenting: what was the question (editorial)? J Am Coll Cardiol 1999;34:1895-1898.
63. McCullough PA, Kuntz RE, Marks KR, Popma JJ. Should we change from aspirin and ticlopidine to aspirin and clopidogrel alter routine coronary stenting? A population-based decision analysis. Circulation 1999;199(suppl I):379.
64. Taniuchi M, Kurz HI, Smith SC, Lasala JM. Ticlopidine or Plavix post stent (TOPPS): randomization to 2-week treatment. Circulation 1999;100(suppl 1):379.
65. Urban P, Gershlick AH, Rupprecht H-J, Bertrand ME. Efficacy of ticlopidine and clopidogrel on the rate of cardiac events after stent implantation: evidence from CLASSICS. Circulation 1999;100(suppl I):379.
66. Müller C, Büttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. Circulation 2000;101:590-593.
67. Moussa I, DeGregorio J, Chui M, Cohen N, Collins M. Prospective experience with clopidogrel use after coronary stent implantation in 1100 consecutive patients. Circulation 1999;100(suppl I):379.
68. Dangas G, Mehran R, Peterson MA, Duncan CC, Paliou MN, Purush A, et al. Combination antiplatelet therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after native coronary stent implantation. Circulation 1999; 100(suppl I):379.
69. Hass WK, Easton JD, Adams HR Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B, for the Ticlopidine Aspirin Stroke Study. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients, N Engl J Med 1989;321:501-507.
70. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220.
71. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998;128:541-544.
72. Carwile JM, Laber DA, Soltero KR, Anstadt MP, Chow TW, Nolasco LH, et al. Thrombotic thrombocytopenic purpura occurring after exposure to clopidogrel. Blood 1999;94(suppl 1, part 2):786.
73. van Hecken A, Depre M, Wynants K, Vanbilloen H, Verbruggen A, Arnout J, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metab Drug Interact 1998;14:193-205.